Results 71 to 80 of about 1,273 (215)
Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial
BMC Infectious Diseases, 2022 Background The efficacy of early treatment with convalescent plasma in patients with COVID-19 is debated. Nothing is known about the potential effect of other plasma components other than anti-SARS-CoV-2 antibodies.Paola Maria Manzini, Giovannino Ciccone, Francesco Giuseppe De Rosa, Rossana Cavallo, Valeria Ghisetti, Sergio D’Antico, Claudia Galassi, Fabio Saccona, Anna Castiglione, Nadia Birocco, Tiziana Francisci, Huijing Hu, Clara Pecoraro, Franca Danielle, Luciana Labanca, Anna Maria Bordiga, Marco Lorenzi, Giovanni Camisasca, Osvaldo Giachino, Mauro Pagliarino, Piero Ottone, Ilvana Tiziana Donatella Scuvera, Roberto Guaschino, Roberto Freilone, Pierluigi Berti, Fabrizia Pittaluga, Maria Avolio, Cristina Costa, Samuele Raso, Aurora Nucci, Massimo Milan, Alessandra Baffa, Alessandra Russo, Antonella Tornello, Laura Maddalena, Grazia Delios, Fabio Paolo Marletto, Anna Grazia De Micheli, Alessio Mattei, Stefano Baldassano, Francesca Canta, Maria Luisa Russo, Daniele Bergamo, Francesco Vitale, Marco Maria Liccardi, Alessandra Chinaglia, Andrea Calcagno, Marcella Converso, Chiara Aldieri, Valentina Libanore, Ilaria Blangetti, Valentina Benedetti, Barbara Mitola, Gitana Scozzari, the PLACO COVID Study Group +54 moredoaj +1 more sourceSomatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas
Molecular Oncology, EarlyView.This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan +6 morewiley +1 more sourceYIPFα1A expression is regulated by multilayered molecular mechanisms
FEBS Open Bio, EarlyView.YIPFα1A, a five‐pass Golgi protein, is regulated at multiple layers. (1) Rare‐codon enrichment drives translation‐coupled mRNA decay. (2) A proximal 3′‐UTR element stabilizes mRNA. (3) A distal 3′‐UTR element included by alternate poly(A) site usage represses translation, which can be overridden by the proximal 3′‐UTR element.Tokio Takaji, Yurika Nakanishi, Nobuhiro Nakamura +2 morewiley +1 more sourceFactors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
Infectious Diseases and Therapy, 2020 Introduction Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus was discovered in Wuhan City, Hubei Province, China, in December 2019.Danyal Ibrahim, Latha Dulipsingh, Lisa Zapatka, Reginald Eadie, Rebecca Crowell, Kendra Williams, Dorothy B. Wakefield, Lisa Cook, Jennifer Puff, Syed A. Hussain +9 moredoaj +1 more sourceIdentifying transcription factors controlling the basal expression of human MRP4 highlights a substantial role for Sp1
FEBS Open Bio, EarlyView.The MRP4 transporter exports several drugs and signaling molecules. Here, we identified key promoter elements regulating basal MRP4 expression. Using reporter assays, we defined a conserved region with essential Sp1 and contributory Ets sites, which controlled basal MRP4 expression.Debora Singer, Angelique Kragl, Katrin Ziems, Juliane Glaubitz, Sophie Grammbauer, Susanne Hildebrandt, Mladen V. Tzvetkov, Gabriele Jedlitschky +7 morewiley +1 more sourceCyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long‐chain fatty acid accumulation after myocardial ischemia–reperfusion in mice
FEBS Open Bio, EarlyView.In a murine model of myocardial ischemia and reperfusion (MI/R), the CD36 azapeptide ligand MPE‐298 reduces cardiac injury and transiently lowers left ventricular long‐chain fatty acids (LCFAs) accumulation 3 h after reperfusion, accompanied by a decrease of oxidative stress and inflammation‐associated genes' expression in the heart and adipose tissue. Jade Gauvin, Naghme Radmannia, David N. Huynh, Liliane Ménard, Caroline Daneault, Maïté Veilleux, Ahsanullah Ahsanullah, André C. Carpentier, William D. Lubell, Matthieu Ruiz, Huy Ong, Sylvie Marleau, Simon‐Pierre Gravel +12 morewiley +1 more sourcePassive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults
Trials, 2021 Background Convalescent plasma is being used widely as a treatment for coronavirus disease 2019 (COVID-19). However, the clinical efficacy of COVID-19 convalescent plasma is unclear.Wesley H. Self, Thomas G. Stewart, Allison P. Wheeler, Wissam El Atrouni, Amanda J. Bistran-Hall, Jonathan D. Casey, Vince D. Cataldo, James D. Chappell, Claudia S. Cohn, Jessica B. Collins, Mark R. Denison, Marjolein de Wit, Sheri L. Dixon, Abhijit Duggal, Terri L. Edwards, Magali J. Fontaine, Adit A. Ginde, Michelle S. Harkins, Thelma Harrington, Estelle S. Harris, Daanish Hoda, Tina S. Ipe, Stuti J. Jaiswal, Nicholas J. Johnson, Alan E. Jones, Maryrose Laguio-Vila, Christopher J. Lindsell, Jason Mallada, Manoj J. Mammen, Ryan A. Metcalf, Elizabeth A. Middleton, Simon Mucha, Hollis R. O’Neal, Sonal R. Pannu, Jill M. Pulley, Xian Qiao, Jay S. Raval, Jillian P. Rhoads, Harry Schrager, Carl Shanholtz, Nathan I. Shapiro, Stephen J. Schrantz, Isaac Thomsen, Krista K. Vermillion, Gordon R. Bernard, Todd W. Rice, For the Passive Immunity Trial for Our Nation (PassITON) Investigators +46 moredoaj +1 more sourceUiO‐66 metal–organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy
FEBS Open Bio, EarlyView.UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.Veronika Huntošová, Grigorii Rakhalskii, Miroslav Almáši +2 morewiley +1 more source
